NCT03904628View on ClinicalTrials.gov

Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

October 31, 2020

Conditions
High-grade Gliomas
Interventions
DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules150mg oral administration, BIW in every 28d

DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules 200mg oral administration, BIW in every 28d

DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules 250mg oral administration, BIW in every 28d

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY